ClinicalTrials.gg
CompletedNCT06192550Updated Feb 13, 2025

Functional Usability and Feasibility Testing of the Profound Matrix™ System

An interventional study of Profound Matrix™ System in Wrinkle and Acne Scars - Mixed Atrophic and Hypertrophic, sponsored by Candela Corporation. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Candela Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.
  • Registered 3 years 1 month after the study started (first participant enrolled Oct 2020, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
193
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Hypertrophy with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Hypertrophy · United States.

Enrollment
2nd of 41
193 · median 30
Started
2020
with 2 others
No phase
34 of 47
6 open now
Registered
41st of 47
by date

Among the 47 studies in Hypertrophy with a site in United States, this one is the 2nd largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2020, is one of 34 with no phase, and was the 41st registered.

Hypertrophy

140 studies on the registry are indexed under Hypertrophy; 23 are open to participants now.

Browse Hypertrophy studies →

Open to participants now

8 of the 47 studies in Hypertrophy with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Hypertrophy studies recruiting now, 3 (23%) set no upper age limit and 7 (54%) stop at 75 or younger; none take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hypertrophy with a site in United States, or all of them as a file.
02

Study summary

This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles and acne scars. Subjects will receive up to three (3) treatments with the Matrix Pro applicator or up to five (5) treatments with the Sublime and/or Sublative Radiofrequency (RF) applicators.

03

Conditions studied

  • Wrinkle
  • Acne Scars - Mixed Atrophic and Hypertrophic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Male or Female
  2. Age 18 to 75
  3. Subjects seeking treatment for facial, abdominal, or back wrinkles reduction, skin texture improvement and/or acne scars appearance improvement and willing to undergo RF treatments for improvement
  4. Presence of at least mild wrinkles or mild acne scars or uneven skin texture, as assessed by the Investigator
  5. Willingness to provide signed, to participate in the study
  6. Willingness to allow photography of treated areas, and to release their use for scientific/educational and/or promotional purposes

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding
  2. Pacemaker or internal defibrillator or any active electrical implant anywhere in the body
  3. Superficial metal or other implants in the treatment area, except superficial dental implants, unless these implants can be removed or covered with rolled gauze during treatment
  4. Current skin cancers in the treatment area or history of melanoma
  5. History of current cancer and subject has undergone chemotherapy within the last 12 months
  6. Severe concurrent conditions, such as cardiac disorders
  7. Impaired immune system due to diseases such as AIDS and , or use of immunosuppressive medications
  8. Herpes Simplex Virus (HSV) in the intended treatment area unless treated following a prophylactic regimen
  9. Poorly controlled endocrine disorders such as diabetes
  10. Active skin condition in the treatment area such as sores, psoriasis, eczema, or rash, open wounds, and severe active inflammatory acne.
  11. History of abnormal wound healing, keloid, or hypertrophic scar formation, as well as very dry and fragile skin
  12. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitis disorders
  13. Known allergy to lidocaine, tetracaine, Xylocaine, epinephrine or ProNox (nitrous oxide (laughing gas))
  14. Patients on systemic therapy in past six months
  15. Is taking medication(s) for which sunlight is a
  16. Tattoos or permanent makeup in the intended treatment area
  17. Excessively tanned skin
  18. Subjects with pigmented lesions that are considered not acceptable by the study investigator or any condition that, in the investigator's opinion, would make it unsafe to treat.
  19. Subject has hair and is unwilling to have hair removed from the treatment area
  20. Subjects has undergone facelift in the last 12 months
  21. Subject has undergone aesthetics treatments/procedures (e.g. facial resurfacing and deep chemical peeling) within the last 4 months) within the intended to treat area
  22. Subject has undergone Botox in the treatment area within the last 3 months
  23. Subject has non-permanent filler in the last 3 months within the intended to treat area
  24. Subject has permanent filler (e.g. silicone) within the intended to treat area
  25. Subject has absorbable facial threads within the last 2 years within the intended to treat area
  26. Subject has non-absorbable facial threads within the intended to treat area aa. Subject is using a topical in the treatment area that the Investigator's deems the subject unsuitable for the study.

bb. In the opinion of the Investigator, the subject is unwilling or unable to adhere to the study requirements

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Group 1: Matrix Pro

    Subjects undergoing treatment with the Matrix Pro applicator.

    Device: Profound Matrix™ System

  • Experimental
    Group 2: Sublime/Sublative

    Subjects undergoing treatment with either 1) Sublime applicator only, 2) Sublative RF applicator only, 3) Combined treatment of Sublime and Sublative RF applicators.

    Device: Profound Matrix™ System

  • Experimental
    Modified Matrix Pro

    Subjects undergoing treatment with a Matrix Pro Modified applicator with lower RF power settings.

    Device: Profound Matrix™ System

Interventions

  • DeviceProfound Matrix™ System

    Study subjects will be treated with the Profound Matrix System

06

What researchers measure

Primary outcomes

  1. Investigator Global Aesthetic Improvement Scale (GAIS): Perceived Improvement in Overall Appearance

    Perceived improvement in overall appearance according to the 5-point Global Aesthetic Improvement Scale from -1= Worse to 3= Very Much Improved as assessed by investigator at study endpoint

    Time frame: 3 months post final treatment

Secondary outcomes

  1. Subject Global Aesthetic Improvement Scale (GAIS): Perceived Improvement in Overall Appearance

    Perceived improvement in overall appearance according to the 5-point Global Aesthetic Improvement Scale from -1= Worse to 3= Very Much Improved as assessed by subject at study endpoint

    Time frame: 3 months post final treatment

07

Study locations

5 sites
  • Candela Institue for Excellence
    Marlborough, Massachusetts 01752, United States
  • OptiSkin
    New York City, New York 10128, United States
  • NY Derm
    New York, New York 10028, United States
  • Laser & Vein Specialists of the Carolinas
    Charlotte, North Carolina 28207, United States
  • Syneron Medical
    Yoqne'am 'Illit, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Sep 2023, 34 months.

Of 78 interventional studies with no phase under Hypertrophy, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 5, 2024
StartActual
Oct 28, 2020
Primary completionActual
Sep 27, 2023
CompletionActual
Dec 29, 2023
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06192550
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Oct 28, 2020
Primary completion
Sep 27, 2023
Completion
Dec 29, 2023
Last update
Feb 13, 2025

Study contacts

Konika Schallen, MD
principal investigator · Candela Medical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion